The Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, Missouri, USA.
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
mSphere. 2018 Nov 21;3(6):e00588-18. doi: 10.1128/mSphereDirect.00588-18.
Strategies to prevent multidrug-resistant organism (MDRO) infections are scarce, but autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal MDRO expansion. AutoFMT involves banking one's feces during a healthy state for later use in restoring gut microbiota following perturbation. This pilot study evaluated the effect of autoFMT on gastrointestinal microbiome taxonomic composition, resistance gene content, and metabolic capacity after exposure to amoxicillin-clavulanic acid (Amox-Clav). Ten healthy participants were enrolled. All received 5 days of Amox-Clav. Half were randomized to autoFMT, derived from stool collected pre-antimicrobial exposure, by enema, and half to saline enema. Participants submitted stool samples pre- and post-Amox-Clav and enema and during a 90-day follow-up period. Shotgun metagenomic sequencing revealed taxonomic composition, resistance gene content, and metabolic capacity. Amox-Clav significantly altered gut taxonomic composition in all participants ( = 10, < 0.01); however, only three participants exhibited major changes at the phylum level following exposure. In the cohort as a whole, beta-lactamase genes were enriched following Amox-Clav ( < 0.05), and predicted metabolic capacity was significantly altered ( < 0.01). Species composition, metabolic capacity, and beta-lactamase abundance returned to pre-antimicrobial exposure state 7 days after either autoFMT or saline enema ( > 0.05, compared to enrollment). Alterations to microbial metabolic capacity occurred following antimicrobial exposure even in participants without substantial taxonomic disruption, potentially creating open niches for pathogen colonization. Our findings suggest that metabolic potential is an important consideration for complete assessment of antimicrobial impact on the microbiome. AutoFMT was well tolerated and may have contributed to phylogenetic recovery. (This study has been registered at ClinicalTrials.gov under identifier NCT02046525.) The spread of multidrug resistance among pathogenic organisms threatens the efficacy of antimicrobial treatment options. The human gut serves as a reservoir for many drug-resistant organisms and their resistance genes, and perturbation of the gut microbiome by antimicrobial exposure can open metabolic niches to resistant pathogens. Once established in the gut, antimicrobial-resistant bacteria can persist even after antimicrobial exposure ceases. Strategies to prevent multidrug-resistant organism (MDRO) infections are scarce, but autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal MDRO expansion. AutoFMT involves banking one's feces during a healthy state for later use in restoring gut microbiota following perturbation. This pilot study evaluated the effect of amoxicillin-clavulanic acid (Amox-Clav) exposure and autoFMT on gastrointestinal microbiome taxonomic composition, resistance gene content, and metabolic capacity. Importantly, we found that metabolic capacity was perturbed even in cases where gross phylogeny remained unchanged and that autoFMT was safe and well tolerated.
预防耐多药生物体(MDRO)感染的策略很少,但自体粪便微生物群移植(autoFMT)可能限制胃肠道 MDRO 的扩张。autoFMT 涉及在健康状态下储存自己的粪便,以备在肠道微生物群受到干扰后用于恢复。这项初步研究评估了暴露于阿莫西林-克拉维酸(Amox-Clav)和 autoFMT 对胃肠道微生物组分类组成、耐药基因含量和代谢能力的影响。
共有 10 名健康参与者入组。所有参与者均接受 5 天的 Amox-Clav 治疗。一半参与者随机接受来自于抗菌暴露前采集的粪便的 autoFMT,通过灌肠进行,另一半接受生理盐水灌肠。参与者在接受 Amox-Clav 和灌肠前以及 90 天的随访期间提交粪便样本。 shotgun 宏基因组测序揭示了分类组成、耐药基因含量和代谢能力。Amox-Clav 显著改变了所有参与者的肠道分类组成(=10,<0.01);然而,只有三名参与者在暴露后出现了门水平的主要变化。在整个队列中,β-内酰胺酶基因在 Amox-Clav 后富集(<0.05),预测的代谢能力也发生了显著改变(<0.01)。在接受 autoFMT 或生理盐水灌肠后 7 天,物种组成、代谢能力和β-内酰胺酶丰度均恢复到抗菌暴露前的状态(>0.05,与入组时相比)。即使在没有明显分类紊乱的参与者中,抗菌药物暴露后微生物代谢能力也发生了改变,这可能为病原体定植创造了开放的生态位。
我们的研究结果表明,代谢能力是评估抗菌药物对微生物组影响的一个重要考虑因素。autoFMT 耐受性良好,可能有助于恢复系统发育。(本研究已在 ClinicalTrials.gov 注册,标识符为 NCT02046525。)耐药生物体在病原体中的传播威胁着抗菌治疗方案的疗效。人类肠道是许多耐药生物体及其耐药基因的储存库,抗菌药物暴露会破坏肠道微生物群,从而为耐药病原体开辟代谢生态位。一旦在肠道中建立,即使在停止使用抗菌药物后,抗药性细菌也能持续存在。预防耐多药生物体(MDRO)感染的策略很少,但自体粪便微生物群移植(autoFMT)可能限制胃肠道 MDRO 的扩张。autoFMT 涉及在健康状态下储存自己的粪便,以备在肠道微生物群受到干扰后用于恢复。
这项初步研究评估了阿莫西林-克拉维酸(Amox-Clav)暴露和 autoFMT 对胃肠道微生物组分类组成、耐药基因含量和代谢能力的影响。重要的是,我们发现即使在宏观进化没有明显改变的情况下,代谢能力也受到了干扰,而且 autoFMT 是安全且耐受良好的。
Eur Arch Otorhinolaryngol. 2000
Front Microbiol. 2022-9-20
Contemp Clin Trials Commun. 2022-3-7
Genome Med. 2020-9-28
Front Immunol. 2019-6-14
Clin Infect Dis. 2018-1-18
Nat Biotechnol. 2017-9-12
Nat Chem Biol. 2017-7
Gastroenterol Clin North Am. 2017-3